Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
FDA: Management of chronic stable angina (vasospastic and exertional), treatment of hypertension.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are inactive.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
>95% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins
92-98% bound to plasma proteins (primarily albumin)
0.2-0.6 L/kg; suggests limited tissue distribution; higher in hepatic cirrhosis
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
IV: 100%; not available orally in this formulation
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
GFR < 30 m L/min: initial dose 2.5 mg/hr; titrate cautiously. No adjustment for GFR ≥ 30.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh Class A: no adjustment. Class B: reduce initial dose by 50%. Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established; no standard dosing recommendations.
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (2.5-3 mg/hr); titrate slowly due to increased sensitivity.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None.
No FDA black box warning.
Hypotension and reflex tachycardia may occur, especially in patients on beta-blockers.,Use caution in patients with congestive heart failure or impaired ventricular function.,May cause worsening of angina on abrupt withdrawal.,Hepatic impairment may increase drug levels; dose adjustment may be needed.,Peripheral edema is common but not due to fluid retention.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to nicardipine or any component of the formulation.,Advanced aortic stenosis.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they may increase nicardipine levels. High fat meals can affect absorption, but since this is IV, dietary restrictions primarily relate to dextrose content for diabetics. No other significant food interactions.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, and growth restriction due to maternal hypotension; avoid use for tocolysis.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Nicardipine is excreted in human milk; estimated infant dose <2% of maternal weight-adjusted dose. M/P ratio: 1.2. Caution advised; monitor infant for hypotension and cardiovascular effects.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustment required based on pharmacokinetic changes; use lowest effective dose; monitor for maternal hypotension and fetal effects.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
CARDENE (nicardipine) in 4.8% dextrose is a dihydropyridine calcium channel blocker used for IV treatment of hypertension. It is light-sensitive; protect from light. Titrate dose by 1-2 mg/hour increments every 5 minutes up to target blood pressure. Do not mix with sodium bicarbonate or lactated Ringer's. Use with caution in patients with coronary artery disease due to reflex tachycardia, and in hepatic impairment as metabolism is hepatic. May cause peripheral edema; monitor for worsening heart failure.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
This medication is given intravenously to lower blood pressure; you will be closely monitored.,Inform your healthcare provider if you have a history of heart disease, liver problems, or if you are pregnant or breastfeeding.,You may experience headache, dizziness, or flushing; report these if severe.,Avoid alcohol consumption while on this medication as it may increase side effects.,This solution contains dextrose; notify your doctor if you have diabetes or need to restrict sugar intake.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs AFEDITAB CR, answered by our medical review team.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is: Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, . AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.